TrYbe™: An Fc-free multispecific Antibody Format. Exemplified With Galvokimig For IL-13, IL-17A & IL-17F Blockade
- Balancing folding, stability, and affinity across dual binding arms to enable robust and consistent target engagement
- Designing architectures that minimise steric interference while preserving full dual-target functionality
- Accelerating early optimisation and decision-making to shorten timelines from discovery to clinical candidate